Skip to content

Shock Efficacy Study Comparing Fixed Tilt and Fixed Pulse Width in a General Implantable-Cardioverter Population

Shock Efficacy, a Randomized Study Comparing Fixed Tilt and Fixed Pulse Width in a General Implantable-Cardioverter Population

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03632057
Acronym
EFICAZ
Enrollment
779
Registered
2018-08-15
Start date
2018-06-06
Completion date
2025-04-18
Last updated
2025-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ventricular Arrythmia

Brief summary

This is a prospective, 1:1 randomized, interventional, multicenter and international trial. Approximately 790 subjects are expected to be enrolled to 40 sites in the south of Europe and Middle East.

Detailed description

The objective of this study is to evaluate and compare the efficacy of the first appropriate shock of an ICD in a ventricular tachyarrhythmia, when the waveform of the shock is programmed with the standard waveform, Fixed Tilt with a value of 65% (Control Group), versus the exclusive waveform programmable in SJM ICDs, Fixed Pulse Width (Study Group), in a standard population of subjects with ICD indication.

Interventions

DEVICEFixed Tilt (65%)

This is the standard group, so device programming for shock energy is the default setting

DEVICEFixed Pulse Width

The device has to be programmed with fixed pulse width for each phase of the biphasic waveform

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects who meet the current ESC indications for ICD or CRT-D implant. This includes upgrades indications from pacemaker to ICD or to CRT-D or replacements of ICDs or CRT-Ds provided that there is no previous record of ineffective shocks * Subjects who are willing to be registered on the Merlin.net remote follow-up program * Subject ≥18 years * Subjects with life expectancy of at least 1 year * Subjects who agree to comply with the follow-up program included in this protocol

Exclusion criteria

* • Subjects on the waiting list for a heart transplant or under consideration for a transplant over the next 12 months * Subjects with Myocardial infarction or unstable angina within 40 days prior to enrollment * Subjects who have undergone a recent cardiac revascularization (PTCA, Stent or CABG) procedure in the 4 weeks prior to enrollment * Functional NYHA Class IV * Subjects who are participating in another ICD or CRT-D study * Subjects who are pregnant at the time of enrollment or women of childbearing potential that do not take contraceptives * Any disability or limitations to correctly understand or complete the study (physical, intellectual, logistical)

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the first appropriate shock to revert a tachyarrhythmia to sinus rhythm5 yearsRate of rhythm conversion from Ventricular Tachyarrhythmia to sinus rhythm by the first appropriate shock programmed to 25 Joules (or equivalent voltage) programming the shock waveform in Fixed Pulse Width (Study Group) versus the Fixed Tilt with value 65% (Control Group).

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026